## Supplemental Figure legends

Supplemental Figure 1. Mean osimertinib concentration-time profile following the administration of osimertinib and dasatinib on cycle 1 day 1.

Supplemental Figure 2. Longitudinal mean concentration-time profile of osimertinib (A) and one of its metabolites AZ13575104 (B) during study treatment.

Supplemental Figure 3. Longitudinal osimertinib-time profile of individual patients.

Supplemental Figure 4. Serial CRIPTO levels in serum.

**Supplemental Figure 1**



**Supplemental Figure 2**



# Supplemental Figure 3



# Supplemental Figure 4